Investor Relations

INVESTORS & MEDIA

INVESTORS
& MEDIA

We are a leading science and technology company that delivers life-transforming medicines for serious diseases.

Founded by physician-scientists nearly 30 years ago, our science-driven approach has resulted in six FDA-approved medicines and numerous product candidates in a range of diseases, including cancer, asthma, pain and infectious diseases.

In addition to our medicines, our innovations include the VelociSuite® technologies, world-class manufacturing operations, one of the largest human sequencing efforts in the world and rapid response technologies being used for global good.

 

NASDAQ REGN

$324.12 7.95 (2.51)%

High 327.16 Low 316.24 Volume 367,982 Market Cap 34.29B
04/26/18 1:13 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Financial information

NEWSROOM

  • Apr 23

    Regeneron Announces Upcoming Investor Conference Presentations

    Read on
  • Apr 09

    Regeneron to Report First Quarter 2018 Financial and Operating Results and Host Conference Call and Webcast on May 3, 2018

    Read on

EVENTS

  • Regeneron Pharmaceuticals Q1 2018 Earnings Conference Call
    May 3, 2018 | 8:30 AM ET

  • J.P. Morgan 2018 Spring Biotech Conference Call Series
    May 8, 2018 | 10:00 AM ET

Events & Presentations

NASDAQ REGN

$324.12 7.95 (2.51)%

High 327.16 Low 316.24 Volume 367,982 Market Cap 34.29B
04/26/18 1:13 PM ET | Minimum 20 minutes delay.

Stock information provided by eSignal.

Stock information

Financial information